Vitamin D status in pediatric irritable bowel syndrome
dc.contributor.author | Nwosu, Benjamin U. | |
dc.contributor.author | Maranda, Louise | |
dc.contributor.author | Candela, Ninfa | |
dc.date | 2022-08-11T08:10:10.000 | |
dc.date.accessioned | 2022-08-23T16:57:50Z | |
dc.date.available | 2022-08-23T16:57:50Z | |
dc.date.issued | 2017-02-13 | |
dc.date.submitted | 2017-02-14 | |
dc.identifier.citation | PLoS One. 2017 Feb 13;12(2):e0172183. doi: 10.1371/journal.pone.0172183. eCollection 2017. <a href="http://dx.doi.org/10.1371/journal.pone.0172183">Link to article on publisher's website</a> | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.doi | 10.1371/journal.pone.0172183 | |
dc.identifier.pmid | 28192499 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/43237 | |
dc.description | <p>Data Availability: Our study data files are publicly deposited in the University of Massachusetts Medical School’s institutional repository, <a href="http://escholarship.umassmed.edu" target="_blank" title="eScholarship@UMMS">eScholarship@UMMS</a>. The permanent link to the data is <a href="http://escholarship.umassmed.edu/pediatrics_data/4/" target="_blank">http://escholarship.umassmed.edu/pediatrics_data/4/</a> or <a href="http://dx.doi.org/10.13028/M27P4Q" target="_blank">http://dx.doi.org/10.13028/M27P4Q</a>.</p> | |
dc.description.abstract | IMPORTANCE: Irritable bowel syndrome (IBS) is associated with significant morbidity in children and adolescents, and the therapeutic efficacy of available treatment options is limited. The role of vitamin D supplementation in pediatric IBS is unclear as the vitamin D status of pediatric patients with IBS is unknown. Equally, the relationship of vitamin D status with psychosomatic symptoms in children and adolescents is unclear. AIM: To characterize the vitamin D status of pediatric patients with IBS using a case-control study design. HYPOTHESIS: Serum 25-hydroxyvitamin D [25(OH)D] concentration will be similar between patients with IBS and controls. SUBJECTS AND METHODS: A retrospective case-controlled study of 116 controls (age 14.6 ± 4.3 y), female (n = 67; 58%) and 55 subjects with IBS (age 16.5 ± 3.1y), female (n = 44; 80%). Overweight was defined as BMI of ≥85th butpercentile, and obesity as BMI ≥95th percentile. Vitamin D deficiency was defined as 25(OH)D of/L, while seasons of vitamin D draw were categorized as summer, winter, spring, and fall. Major psychosomatic manifestations included in the analysis were depression, anxiety, and migraine. RESULTS: More than 50% of IBS subjects had vitamin D deficiency at a cut-off point of/L (53% vs. 27%, p = 0.001); and >90% of IBS subjects had vitamin D deficiency at a cut-off point of/L (93% vs. 75%, p = 0.006). IBS subjects had significantly lower mean 25(OH)D: 53.2 ± 15.8 nmol/L vs. 65.2 ± 28.0 nmol/L, p = 0.003; and albumin: 6.2 ± 0.6 vs. 6.5 ± 0.6 μmol/L, p = 0.0.01. IBS subjects with migraine had significantly lower mean 25(OH)D concentration compared to controls (p = 0.01). BMI z-score was similar between the controls and IBS subjects (0.5 ± 1.4 vs. 1.2 ± 2.9, p = 0.11). CONCLUSIONS: Pediatric patients with IBS had significantly lower 25(OH)D concentration compared to controls despite having similar mean BMI values as controls. Only 7% of the children and adolescents with IBS were vitamin D sufficient, and >50% of the subjects with IBS had vitamin D deficiency. This is a much higher prevalence of vitamin D deficiency compared to IBD and other malabsorption syndromes. Monitoring for vitamin D deficiency should be part of the routine care for patients with IBS. Randomized control trials are warranted to determine the role of adjunctive vitamin D therapy in pediatric IBS. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28192499&dopt=Abstract">Link to article in PubMed</a> | |
dc.rights | Copyright: © 2017 Nwosu et al. | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Vitamin D | |
dc.subject | Irritable bowel syndrome | |
dc.subject | Vitamin D deficiency | |
dc.subject | Pediatrics | |
dc.subject | Adolescents | |
dc.subject | Inflammatory bowel disease | |
dc.subject | Albumins | |
dc.subject | Migraine | |
dc.subject | Digestive System Diseases | |
dc.subject | Endocrinology, Diabetes, and Metabolism | |
dc.subject | Gastroenterology | |
dc.subject | Pediatrics | |
dc.title | Vitamin D status in pediatric irritable bowel syndrome | |
dc.type | Journal Article | |
dc.source.journaltitle | PLoS One | |
dc.source.volume | 12 | |
dc.source.issue | 2 | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1059&context=peds_endocrinology&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/peds_endocrinology/60 | |
dc.identifier.contextkey | 9683766 | |
refterms.dateFOA | 2022-08-23T16:57:50Z | |
html.description.abstract | <p>IMPORTANCE: Irritable bowel syndrome (IBS) is associated with significant morbidity in children and adolescents, and the therapeutic efficacy of available treatment options is limited. The role of vitamin D supplementation in pediatric IBS is unclear as the vitamin D status of pediatric patients with IBS is unknown. Equally, the relationship of vitamin D status with psychosomatic symptoms in children and adolescents is unclear.</p> <p>AIM: To characterize the vitamin D status of pediatric patients with IBS using a case-control study design.</p> <p>HYPOTHESIS: Serum 25-hydroxyvitamin D [25(OH)D] concentration will be similar between patients with IBS and controls.</p> <p>SUBJECTS AND METHODS: A retrospective case-controlled study of 116 controls (age 14.6 ± 4.3 y), female (n = 67; 58%) and 55 subjects with IBS (age 16.5 ± 3.1y), female (n = 44; 80%). Overweight was defined as BMI of ≥85th butpercentile, and obesity as BMI ≥95th percentile. Vitamin D deficiency was defined as 25(OH)D of/L, while seasons of vitamin D draw were categorized as summer, winter, spring, and fall. Major psychosomatic manifestations included in the analysis were depression, anxiety, and migraine.</p> <p>RESULTS: More than 50% of IBS subjects had vitamin D deficiency at a cut-off point of/L (53% vs. 27%, p = 0.001); and >90% of IBS subjects had vitamin D deficiency at a cut-off point of/L (93% vs. 75%, p = 0.006). IBS subjects had significantly lower mean 25(OH)D: 53.2 ± 15.8 nmol/L vs. 65.2 ± 28.0 nmol/L, p = 0.003; and albumin: 6.2 ± 0.6 vs. 6.5 ± 0.6 μmol/L, p = 0.0.01. IBS subjects with migraine had significantly lower mean 25(OH)D concentration compared to controls (p = 0.01). BMI z-score was similar between the controls and IBS subjects (0.5 ± 1.4 vs. 1.2 ± 2.9, p = 0.11).</p> <p>CONCLUSIONS: Pediatric patients with IBS had significantly lower 25(OH)D concentration compared to controls despite having similar mean BMI values as controls. Only 7% of the children and adolescents with IBS were vitamin D sufficient, and >50% of the subjects with IBS had vitamin D deficiency. This is a much higher prevalence of vitamin D deficiency compared to IBD and other malabsorption syndromes. Monitoring for vitamin D deficiency should be part of the routine care for patients with IBS. Randomized control trials are warranted to determine the role of adjunctive vitamin D therapy in pediatric IBS.</p> | |
dc.identifier.submissionpath | peds_endocrinology/60 | |
dc.contributor.department | Division of Gastroenterology, Department of Pediatrics | |
dc.contributor.department | Department of Quantitative Health Sciences | |
dc.contributor.department | Division of Endocrinology, Department of Pediatrics | |
dc.source.pages | e0172183 |